BSF Enterprise PLC on Friday said that 3D Bio-Tissues Ltd has signed a proof-of-concept deal with a large cosmetic company to test its lipopeptide, Etsyl, for use in skin cream cosmetics.

BSF Enterprise is a London-based biotechnology investor. It owns 100% of 3D Bio-Tissues, a UK-based clinical and cellular agriculture company.

According to BSF, the deal will test the suitability of the 3DBT’s proprietary lipopeptide product, Etsyl, for use in skin cream cosmetic solutions. Though the cosmetic company went unnamed, BSF said that it specialises in the research and development of bioactive ingredients for skin care which, with proven efficacy, can aid in anti-ageing, moisturising and acne control.

On Friday, BSF also told investors that 3DBT has signed two new staff members, after receiving a €612,000 grant from the European Institute of Innovation and Technology in September. The new staff will focus on securing additional procurement, manufacturing and distribution partnerships in the food-tech and biotech sectors.

‘We are delighted to be working with one of the world’s largest cosmetic companies, which highlights the potential of our Etsyl product and the diverse applications of our technology. Furthermore, with an enlarged team in hand, we hope to secure further partnerships and sales for our various product offerings at an accelerated pace, and we look to the future with confidence,’ said Che Connon, chief executive of 3DBT and managing director of BSF.

BSF Enterprise shares were trading 1.9% higher at 9.17 pence each in London on Friday morning.

Copyright 2023 Alliance News Ltd. All Rights Reserved.